Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 18.9% | 21.6% | 22.4% | 27.4% | 29.6% | 31.3% | 39.6% | 46.0% | 54.9% | 60.5% | 63.9% | 79.9% | 82.2% | 80.2% | 76.0% | 71.2% | 69.7% | 71.2% | 72.0% | 88.1% |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Microsoft Corp's last 12-month Return on Equity (ROE) is 81.3%, based on the financial report for Sep 30, 2024 (Q3 2024). The average annual Return on Equity (ROE) for Novo Nordisk A/S have been 75.8% over the past three years, and 78.2% over the past five years.
As of today, Novo Nordisk A/S's Return on Equity (ROE) is 81.3%, which is higher than industry median of (51.8%). It indicates that Novo Nordisk A/S's Return on Equity (ROE) is Good.